Amended Statement of Beneficial Ownership (sc 13d/a)
October 23 2020 - 5:06PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
13D/A
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Albireo
Pharma, Inc.
(Name of Issuer)
Common Stock, $0.01 par value
(Title of Class of Securities)
01345P 106
(CUSIP
Number)
Stefan Fischer
TVM Capital
Ottostrasse
4
80333 Munich, Germany
(49) 89998992-48
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
November 6, 2019
(Date of Event Which Requires Filing of this Statement)
If the filing person has
previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box. ☐
Note: Schedules filed in paper format shall
include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.
*
|
The remainder of this cover page shall be filled out for a reporting persons initial filing on this form
with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
|
The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities
Exchange Act of 1934, as amended (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|
|
|
|
|
|
|
1.
|
|
Names of
Reporting Persons.
TVM Life Science Ventures VI L.P.
|
2.
|
|
Check the Appropriate Box if a Member
of a Group (See Instructions)
(a) ☐ (b) ☐
|
3.
|
|
SEC Use Only
|
4.
|
|
Source of Funds (See Instructions)
WC
|
5.
|
|
Check if Disclosure of Legal
Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐
|
6.
|
|
Citizenship or Place of
Organization
Cayman Islands
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With
|
|
7.
|
|
Sole Voting Power
0
|
|
8.
|
|
Shared Voting Power
0
|
|
9.
|
|
Sole Dispositive Power
0
|
|
10.
|
|
Shared Dispositive Power
0
|
11.
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person
0
|
12.
|
|
Check if the Aggregate Amount in Row
(11) Excludes Certain Shares (See Instructions)
☐
|
13.
|
|
Percent of Class Represented by Amount
in Row (11)
0%
|
14.
|
|
Type of Reporting Person (See
Instructions)
PN
|
|
|
|
|
|
|
|
1.
|
|
Names of
Reporting Persons.
TVM Life Science Ventures VI GmbH & Co. KG
|
2.
|
|
Check the Appropriate Box if a Member
of a Group (See Instructions)
(a) ☐ (b) ☐
|
3.
|
|
SEC Use Only
|
4.
|
|
Source of Funds (See Instructions)
WC
|
5.
|
|
Check if Disclosure of Legal
Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐
|
6.
|
|
Citizenship or Place of
Organization
Germany
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With
|
|
7.
|
|
Sole Voting Power
0
|
|
8.
|
|
Shared Voting Power
0
|
|
9.
|
|
Sole Dispositive Power
0
|
|
10.
|
|
Shared Dispositive Power
0
|
11.
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person
0
|
12.
|
|
Check if the Aggregate Amount in Row
(11) Excludes Certain Shares (See Instructions)
☐
|
13.
|
|
Percent of Class Represented by Amount
in Row (11)
0%
|
14.
|
|
Type of Reporting Person (See
Instructions)
PN
|
|
|
|
|
|
|
|
1.
|
|
Names of
Reporting Persons.
TVM Life Science Ventures Management VI L.P.
|
2.
|
|
Check the Appropriate Box if a Member
of a Group (See Instructions)
(a) ☐ (b) ☐
|
3.
|
|
SEC Use Only
|
4.
|
|
Source of Funds (See Instructions)
AF
|
5.
|
|
Check if Disclosure of Legal
Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐
|
6.
|
|
Citizenship or Place of
Organization
Delaware
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With
|
|
7.
|
|
Sole Voting Power
0
|
|
8.
|
|
Shared Voting Power
0
|
|
9.
|
|
Sole Dispositive Power
0
|
|
10.
|
|
Shared Dispositive Power
0
|
11.
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person
0
|
12.
|
|
Check if the Aggregate Amount in Row
(11) Excludes Certain Shares (See Instructions)
☐
|
13.
|
|
Percent of Class Represented by Amount
in Row (11)
0%
|
14.
|
|
Type of Reporting Person (See
Instructions)
PN
|
|
|
|
|
|
|
|
1.
|
|
Names of
Reporting Persons.
Hubert Birner
|
2.
|
|
Check the Appropriate Box if a Member
of a Group (See Instructions)
(a) ☐ (b) ☐
|
3.
|
|
SEC Use Only
|
4.
|
|
Source of Funds (See Instructions)
AF
|
5.
|
|
Check if Disclosure of Legal
Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐
|
6.
|
|
Citizenship or Place of
Organization
Germany
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With
|
|
7.
|
|
Sole Voting Power
0
|
|
8.
|
|
Shared Voting Power
0
|
|
9.
|
|
Sole Dispositive Power
0
|
|
10.
|
|
Shared Dispositive Power
0
|
11.
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person
0
|
12.
|
|
Check if the Aggregate Amount in Row
(11) Excludes Certain Shares (See Instructions)
☐
|
13.
|
|
Percent of Class Represented by Amount
in Row (11)
0%
|
14.
|
|
Type of Reporting Person (See
Instructions)
IN
|
|
|
|
|
|
|
|
1.
|
|
Names of
Reporting Persons.
Stefan Fischer
|
2.
|
|
Check the Appropriate Box if a Member
of a Group (See Instructions)
(a) ☐ (b) ☐
|
3.
|
|
SEC Use Only
|
4.
|
|
Source of Funds (See Instructions)
AF
|
5.
|
|
Check if Disclosure of Legal
Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐
|
6.
|
|
Citizenship or Place of
Organization
Germany
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With
|
|
7.
|
|
Sole Voting Power
0
|
|
8.
|
|
Shared Voting Power
0
|
|
9.
|
|
Sole Dispositive Power
0
|
|
10.
|
|
Shared Dispositive Power
0
|
11.
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person
0
|
12.
|
|
Check if the Aggregate Amount in Row
(11) Excludes Certain Shares (See Instructions)
☐
|
13.
|
|
Percent of Class Represented by Amount
in Row (11)
0%
|
14.
|
|
Type of Reporting Person (See
Instructions)
IN
|
Item 5.
|
Interest in Securities of the Issuer
|
Item 5
|
of the Schedule 13D is hereby amended and supplemented as follows:
|
|
(a)-(b)
|
The information set forth in rows 7 through 13 of the cover pages to this Schedule 13D is incorporated by
reference.
|
|
(c)
|
The Reporting Persons sold the remaining shares beneficially owned by the Reporting Persons in open market
transactions on September 9 through September 11 of 2020, at prices ranging from $38.47 to $40.71 per share.
|
|
(e)
|
The Reporting Persons ceased being the beneficial owners of greater than 5% of the Issuers shares of
Common Stock on November 6, 2019.
|
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
Dated: October 23, 2020
TVM LIFE SCIENCE VENTURES VI L.P.
|
|
|
By:
|
|
TVM LIFE SCIENCE VENTURES MANAGEMENT VI L.P., its Managing Limited Partner
|
|
|
|
|
|
|
|
By:
|
|
/s/ Josef Moosholzer
|
|
|
Name:
|
|
Josef Moosholzer
|
|
|
Title:
|
|
Treasurer
|
TVM LIFE SCIENCE VENTURES VI GMBH & CO. KG
|
|
|
By:
|
|
TVM LIFE SCIENCE VENTURES MANAGEMENT VI L.P., its Managing Limited Partner
|
|
|
|
|
|
|
|
By:
|
|
/s/ Josef Moosholzer
|
|
|
Name:
|
|
Josef Moosholzer
|
|
|
Title:
|
|
Treasurer
|
TVM LIFE SCIENCE VENTURES MANAGEMENT VI L.P.
|
|
|
By:
|
|
/s/ Josef Moosholzer
|
Name:
|
|
Josef Moosholzer
|
Title:
|
|
Treasurer
|
|
/s/ Hubert Birner
|
Hubert Birner
|
|
/s/ Stefan Fischer
|
Stefan Fischer
|
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Apr 2023 to Apr 2024